Dynavax Technologies Corporation  (DVAX)
Other Ticker:  
Price: $13.6400 $-0.09 -0.655%
Day's High: $13.85 Week Perf: 0.52 %
Day's Low: $ 13.57 30 Day Perf: -9.01 %
Volume (M): 1,015 52 Wk High: $ 15.12
Volume (M$): $ 13,847 52 Wk Avg: $11.86
Open: $13.76 52 Wk Low: $9.42

 Market Capitalization (Millions $) 2,075
 Shares Outstanding (Millions) 152
 Employees 235
 Revenues (TTM) (Millions $) 459
 Net Income (TTM) (Millions $) 110
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 5

Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company that develops and commercializes novel vaccines and therapeutics to prevent infectious diseases, cancer, and chronic inflammatory diseases. The company is headquartered in Emeryville, California, and was founded in 199

Dynavax's proprietary technology platforms include the Toll-like Receptor (TLR) and the C-Class CpG deoxyribonucleic acid (CpG DNA) technologies. These platforms stimulate the innate immune system and enhance the body's immune response to various pathogens and tumor antigens.

The company's lead product candidate is HEPLISAV-B, which is an adult hepatitis B vaccine designed to provide faster and more effective protection against hepatitis B compared to traditional vaccines. HEPLISAV-B was approved by the US Food and Drug Administration (FDA) in November 201

Dynavax is also developing SD-101, an investigational TLR9 agonist in phase 3 clinical trials for the treatment of advanced melanoma in combination with Keytruda. The company is also developing DV281, an investigational TLR7/8 agonist in phase 1 clinical trials for the treatment of non-small cell lung cancer.

In addition, Dynavax has partnerships and collaborations with several leading pharmaceutical companies and organizations, including AstraZeneca, GlaxoSmithKline, and the Bill & Melinda Gates Foundation.

Dynavax has a strong financial position, with a market capitalization of approximately $5 billion as of September 202 The company's total revenue for the second quarter of 2021 was $28.1 million, compared to $0 million for the same period in 2020. The company's net loss for the second quarter of 2021 was $68.7 million, compared to $31 million for the same period in 2020.

Overall, Dynavax Technologies Corp is a leading biopharmaceutical company with a promising pipeline of innovative vaccines and therapeutics for the prevention and treatment of infectious and chronic diseases. The company's unique technology platforms and strategic partnerships position it well for continued success in the biopharmaceutical industry.

   Company Address: 2100 Powell Street Emeryville 94608 CA
   Company Phone Number: 848-5100   Stock Exchange / Ticker: NASDAQ DVAX
   DVAX is expected to report next financial results on November 02, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Cannapharmarx Inc

Major Pharmaceutical Preparations company, contraction in the company results all over fiscal first quarter of 2023

The Major Pharmaceutical Preparations industry observers start to interpret the first quarter of 2023 performance. Now they monitor operating shortfall of $-0.720277 million, from the company, which hasn't cited any top-line still, for the respective January to March 31 2023 quarter.

Benitec Biopharma Inc

Benitec Biopharma Inc Revolutionizes the Biotech Industry with Remarkable Q2 2023 Financial Performance!

Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.

Kintara Therapeutics Inc

Kintara Therapeutics Inc Faces Challenging Times as Fourth Quarter Earnings Plunge, Sparking Investor Worries

Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.

Integrated Biopharma Inc

INBPsn Unveil Latest Financial Results

Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.

Rezolute Inc

Major Decline in Company Conduct Signals Troubling Times Ahead

Despite some positive momentum in recent weeks, Rezolute Inc (RZLT) remains an overlooked player in the Major Pharmaceutical Preparations sector. The company's financial numbers paint a gloomy picture, indicating significant operating shortfalls and a net deficit.
In the fourth quarter of 2023, Rezolute Inc reported an operating shortfall of $-14.238 million, demonstrating a worsening financial situation. Although the company has not disclosed its revenue, it is clear that its current revenue figures are not helping to alleviate concerns. Comparing it to the fourth quarter of 2022, where Rezolute Inc reported an operating shortfall of $-11.3 million, it is evident that the company's financial woes have only worsened over time.
The shortfall of $-12.728 million reported in the comparable three months preceding last year is also a cause for concern. The fact that this figure increased from $-9.423 million is alarming and suggests a lack of progress in addressing financial challenges. Additionally, the company reported a net deficit of $-51.79 million, further highlighting its troubled financial state.


Dynavax Technologies's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com